Fever of Unknown Origin and Multidrug Resistant Organism Colonization in AML Patients.
Acute myeloid leukaemia
Colonization
Fever of unknown origin
Multidrug-resistant organism
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
11
2022
accepted:
31
12
2022
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
Colonization by multidrug-resistant organisms (MDRO) is a frequent complication in hematologic departments, which puts patients at risk of life-threatening bacterial sepsis. Fever of unknown origin (FUO) is a condition related to the delivery of chemotherapy in hematologic malignancies, in which the use of antibiotics is debated. The incidence, risk factors, and influence on the outcome of these conditions in patients with acute myeloid leukemia (AML) are not clearly defined. We retrospectively analyzed 132 consecutive admissions of non-promyelocytic AML patients at the Hematology Unit of the University Tor Vergata in Rome between June 2019 and February 2022. MDRO swab-based screening was performed in all patients on the day of admission and once weekly after that. FUO was defined as fever with no evidence of infection. Of 132 consecutive hospitalizations (69 AML patients), MDRO colonization was observed in 35 cases (26%) and resulted independently related to a previous MDRO colonization (p=0.001) and length of hospitalization (p=0.03). The colonization persistence rate in subsequent admissions was 64%. MDRO-related bloodstream infection was observed in 8 patients (23%) and correlated with grade III/IV mucositis (p=0.008) and length of hospitalization (p=0.02). FUO occurred in 68 cases (51%) and correlated with an absolute neutrophilic count <500μ/L at admission (0.04). In our experience, MDRO colonization is a frequent and difficult-to-eradicate condition that can arise at all stages of treatment. Prompt discharge of patients as soon as clinical conditions allow could limit the spread of MDRO. In addition, the appropriate use of antibiotics, especially in the case of FUO, and the contraction of hospitalization length, when feasible, are measures to tackle the further spread of MDRO.
Sections du résumé
Background
UNASSIGNED
Colonization by multidrug-resistant organisms (MDRO) is a frequent complication in hematologic departments, which puts patients at risk of life-threatening bacterial sepsis. Fever of unknown origin (FUO) is a condition related to the delivery of chemotherapy in hematologic malignancies, in which the use of antibiotics is debated. The incidence, risk factors, and influence on the outcome of these conditions in patients with acute myeloid leukemia (AML) are not clearly defined.
Methods
UNASSIGNED
We retrospectively analyzed 132 consecutive admissions of non-promyelocytic AML patients at the Hematology Unit of the University Tor Vergata in Rome between June 2019 and February 2022. MDRO swab-based screening was performed in all patients on the day of admission and once weekly after that. FUO was defined as fever with no evidence of infection.
Results
UNASSIGNED
Of 132 consecutive hospitalizations (69 AML patients), MDRO colonization was observed in 35 cases (26%) and resulted independently related to a previous MDRO colonization (p=0.001) and length of hospitalization (p=0.03). The colonization persistence rate in subsequent admissions was 64%. MDRO-related bloodstream infection was observed in 8 patients (23%) and correlated with grade III/IV mucositis (p=0.008) and length of hospitalization (p=0.02). FUO occurred in 68 cases (51%) and correlated with an absolute neutrophilic count <500μ/L at admission (0.04).
Conclusion
UNASSIGNED
In our experience, MDRO colonization is a frequent and difficult-to-eradicate condition that can arise at all stages of treatment. Prompt discharge of patients as soon as clinical conditions allow could limit the spread of MDRO. In addition, the appropriate use of antibiotics, especially in the case of FUO, and the contraction of hospitalization length, when feasible, are measures to tackle the further spread of MDRO.
Identifiants
pubmed: 36660358
doi: 10.4084/MJHID.2023.013
pii: mjhid-15-1-e2023013
pmc: PMC9833311
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2023013Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest.
Références
Haematologica. 2013 Dec;98(12):1826-35
pubmed: 24323983
Leuk Lymphoma. 2008 Mar;49(3):495-501
pubmed: 18297526
PLoS One. 2021 Jul 29;16(7):e0253842
pubmed: 34324506
Blood. 2017 Feb 2;129(5):587-597
pubmed: 27827823
JAMA. 2001 Oct 17;286(15):1857-62
pubmed: 11597287
Cancer. 1998 Jul 15;83(2):291-301
pubmed: 9669812
Clin Exp Dent Res. 2020 Feb;6(1):90-99
pubmed: 32067405
J Infect. 2014 Apr;68(4):321-31
pubmed: 24370562
Future Microbiol. 2016 Jun;11:767-80
pubmed: 27196948
J Clin Med. 2019 Nov 15;8(11):
pubmed: 31731650
Lancet. 2010 Feb 6;375(9713):463-74
pubmed: 20097417
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Ann Hematol. 2017 Nov;96(11):1775-1792
pubmed: 28856437
Int J Nurs Stud. 2019 Jan;89:80-87
pubmed: 30352321
Infection. 2007 Dec;35(6):421-7
pubmed: 17926001
PLoS One. 2019 Jan 23;14(1):e0210991
pubmed: 30673776
Infect Dis (Lond). 2017 Nov - Dec;49(11-12):799-808
pubmed: 28683646
N Engl J Med. 1994 Apr 28;330(17):1240-1
pubmed: 8139646
Postgrad Med. 1981 Feb;69(2):103-8, 111-2
pubmed: 7454641
J Hosp Infect. 2013 Jun;84(2):132-7
pubmed: 23608003
Haematol Blood Transfus. 1990;33:322-5
pubmed: 2182426
Lancet Infect Dis. 2016 Jul;16(7):819-827
pubmed: 26947523
Cancer. 2016 Jul 15;122(14):2186-96
pubmed: 27142181
Emerg Infect Dis. 2002 Mar;8(3):278-82
pubmed: 11927025
Support Care Cancer. 2021 Oct;29(10):6061-6068
pubmed: 33788003
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e27-e32
pubmed: 28844403
Cancer. 2018 Jan 15;124(2):286-296
pubmed: 28960264
Blood Adv. 2021 Jan 12;5(1):176-184
pubmed: 33570629
Ann Hematol. 2018 Sep;97(9):1717-1726
pubmed: 29705860
Clin Infect Dis. 2020 Jun 24;71(1):63-71
pubmed: 31436833
Ann Hematol. 2016 Jun;95(7):1169-76
pubmed: 27118539
Curr Opin Hematol. 2012 Jan;19(1):21-6
pubmed: 22080847
J Infect Dis. 2008 Apr 15;197(8):1079-81
pubmed: 18419525
Mediterr J Hematol Infect Dis. 2018 May 01;10(1):e2018025
pubmed: 29755703
Crit Rev Oncol Hematol. 2016 May;101:125-30
pubmed: 26995082
Leuk Res. 2011 Oct;35(10):1294-6
pubmed: 21831426
Cancers (Basel). 2020 Jan 02;12(1):
pubmed: 31906489
Leuk Res. 2002 Jun;26(6):539-43
pubmed: 12007501
PLoS One. 2019 Dec 10;14(12):e0225765
pubmed: 31821331